Skip to content
Review

Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents, 2026-2027: Technical Report.

Unknown authors
Sep 2026 · Pediatrics · 1 citation
Medicine

TL;DR

The rationale is presented for recommending vaccination in all infants and children 6 through 23 months of age, children 6 months through 18 years of age who are moderately or severely immunocompromised, and children 2 through 18 years of age in certain additional risk groups, including those at high risk of severe COVID-19.

Abstract

This technical report accompanies the American Academy of Pediatrics policy statement recommendations for COVID-19 vaccination during the 2026-2027 respiratory virus season. The rationale is presented for recommending vaccination in all infants and children 6 through 23 months of age, children 6 months through 18 years of age who are moderately or severely immunocompromised, and children 2 through 18 years of age in certain additional risk groups, including those at high risk of severe COVID-19, residents of long-term care facilities or other congregate settings, children who have never been vaccinated against COVID-19, and children whose household contacts are at high risk for severe COVID-19. The report synthesizes currently available evidence on SARS-CoV-2 epidemiology, disease burden, COVID-19 vaccine effectiveness, vaccine safety, and vaccine cost-effectiveness in pediatric populations. Additionally, the report provides an overview of available COVID-19 vaccine products, formulations, storage and handling considerations, and coadministration with other immunizations.

View source

Similar papers

Review Sep 2026

Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents, 2026-2027: Policy Statement.

This policy statement updates the recommendations of the American Academy of Pediatrics (AAP) for the use of COVID-19 vaccines in the prevention of severe COVID-19 in children. A review of evidence supporting these recommendations is in the accompanying technical report (https://doi.org/10.1542/peds.2026-079046). These...

Unknown authors · 0 citations
Review Sep 2026

Recommendations for the Prevention of Respiratory Syncytial Virus Disease in Infants and Children: Technical Report.

This technical report accompanies the American Academy of Pediatrics (AAP) policy statement (https://doi.org/10.1542/peds.2026-079047) and recommendations for respiratory syncytial virus (RSV) immunization during the 2026-2027 RSV season. The rationale is presented for recommending immunization of all infants younger t...

Unknown authors · 0 citations
Sep 2026

Evaluating access to COVID-19 vaccines for children and adolescents in North Carolina through community pharmacies, 2021-2023.

INTRODUCTION Pharmacists' impact on adult immunization access is well-documented, but limited data exist supporting involvement in vaccination efforts for individuals under 18 years. This study examined trends in child and adolescent COVID-19 vaccinations delivered by pharmacists in North Carolina. METHODS COVID-19 V...

Carrie M. Blanchard, Jenny Myers, Anna Louise McNabb et al. · 0 citations
Review Open access Sep 2026

Self-reported reactogenicity after COVID-19 vaccination with and without influenza vaccine coadministration during pregnancy in Canada.

COVID-19 vaccination in pregnancy, with or without influenza vaccine coadministration, was safe and well-tolerated by survey respondents and no new or worsening health problems were reported after coadministration of COVID-19 and influenza vaccines during pregnancy.

Sophie Tran, E. McClymont, S. Blitz et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.